Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19

Main objective To assess respiratory sequelae after SARS-CoV-2 infection in hospitalized patients with severe pneumonia requiring oxygen supply and followed up for 6 months after hospital discharge (see primary and secondary outcomes). Secondary objectives To describe pulmonary sequelae according to : * the unit in which the patient was hospitalized, * the maximum oxygen flow rate required during hospitalization, * McCabe score, * age, * tobacco consumption, * biological data (e.g. blood count, CRP, fibrinogen, LDH, albumin, D-dimer, ferritin), * number of days from onset of symptoms to hospitalization, * co-morbidities (e.g. diabetes, hypertension, coronary artery disease/heart failure, mild to moderate COPD/respiratory failure, overweight), * concomitant treatments (e.g. non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressants, ACE inhibitors) * specific drug treatments administered to treat COVID-19 infection, * non-drug treatments (invasive ventilation, non-invasive ventilation, postural treatment) to manage respiratory disorders of COVID-19 infection. To assess the impact of factors of social inequality on the severity of COVID-19 infection. Conduct of research Patients who have been hospitalized for severe pneumonia due to CoV-2 SARS infection will be seen in consultation at approximately 3 and 6 months after hospital discharge, as per standard practice.